1. Home
  2. CBOE vs NTRA Comparison

CBOE vs NTRA Comparison

Compare CBOE & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cboe Global Markets Inc.

CBOE

Cboe Global Markets Inc.

HOLD

Current Price

$248.99

Market Cap

25.6B

Sector

Finance

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$279.32

Market Cap

29.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBOE
NTRA
Founded
1973
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.6B
29.1B
IPO Year
2010
2015

Fundamental Metrics

Financial Performance
Metric
CBOE
NTRA
Price
$248.99
$279.32
Analyst Decision
Hold
Strong Buy
Analyst Count
9
15
Target Price
$289.44
$259.07
AVG Volume (30 Days)
1.8M
1.5M
Earning Date
05-01-2026
05-07-2026
Dividend Yield
0.94%
N/A
EPS Growth
44.52
0.65
EPS
3.66
N/A
Revenue
$2,229,100,000.00
$210,939,000.00
Revenue This Year
N/A
$18.08
Revenue Next Year
$3.54
$19.65
P/E Ratio
$68.01
N/A
Revenue Growth
239.31
N/A
52 Week Low
$227.15
$131.81
52 Week High
$371.18
$279.42

Technical Indicators

Market Signals
Indicator
CBOE
NTRA
Relative Strength Index (RSI) 35.93 78.21
Support Level $241.99 $186.96
Resistance Level $255.72 N/A
Average True Range (ATR) 12.92 13.08
MACD -0.32 4.73
Stochastic Oscillator 29.84 99.56

Price Performance

Historical Comparison
CBOE
NTRA

About CBOE Cboe Global Markets Inc.

Founded in 1973, Cboe controls the largest option exchange in the US, which provides around 60% of the firm's revenue. The company is best known for its proprietary S&P 500 and VIX index options, which it offers through an exclusive contract with S&P Global. The firm moved into US and European equities through the $3.4 billion acquisition of BATS in 2017. Cboe has continued to look to expand internationally, using acquisitions to build a presence in both Canada and Australia.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: